Abstract
Background: The current pandemic outbreak of COVID-19 due to viral infections by SARS-CoV-2 has now become associated with severe commotion on global healthcare and the economy.
Objective: In this extreme situation, when vaccine or effective new drugs against COVID-19 are still not available, the only quick and feasible therapeutic alternative would be the drug repurposing approach. Methods: In the present work, in silico screening of some anti-viral and antiprotozoal drugs was performed based on docking using Autodock. Results: Two known anti-viral drugs, sorivudine and noricumazole B, are predicted to bind to the active site of the viral proteases, namely cysteine-like protease or 3CL protease (3CLpro) and papain- like protease (PLpro), respectively, with a highly favorable free energy of binding. Further, the promising molecules were subjected for checking their activity on other molecular targets in SARS-CoV-2 like spike protein S1, RNA dependent RNA polymerase (RdRp), and angiotensin converting enzyme 2 (ACE2) receptor. But the compounds were found non-effective on the rest of the molecular targets. Conclusion: Sorivudine alone or a combination of sorivudine and noricumazole B may be administered to impede viral replication, though the predicted drug likeliness of noricumazole B is not much satisfactory. These observations are solely based on the results from blind docking with protein molecules and need to be further corroborated with experimental results.Keywords: Cysteine like protease, papain-like protease, molecular docking, anti-viral repurposing, sorivudine, noricumazole B.
Graphical Abstract
Coronaviruses
Title:Docking Studies with Multiple Molecular Targets Associated with SARSCoV- 2 for Drug Repurposing
Volume: 2 Issue: 8
Author(s): Shiwani Rana, Meghali Panwar and Kalyan Sundar Ghosh*
Affiliation:
- Department of Chemistry, National Institute of Technology Hamirpur, H.P. 177005,India
Keywords: Cysteine like protease, papain-like protease, molecular docking, anti-viral repurposing, sorivudine, noricumazole B.
Abstract: Background: The current pandemic outbreak of COVID-19 due to viral infections by SARS-CoV-2 has now become associated with severe commotion on global healthcare and the economy.
Objective: In this extreme situation, when vaccine or effective new drugs against COVID-19 are still not available, the only quick and feasible therapeutic alternative would be the drug repurposing approach. Methods: In the present work, in silico screening of some anti-viral and antiprotozoal drugs was performed based on docking using Autodock. Results: Two known anti-viral drugs, sorivudine and noricumazole B, are predicted to bind to the active site of the viral proteases, namely cysteine-like protease or 3CL protease (3CLpro) and papain- like protease (PLpro), respectively, with a highly favorable free energy of binding. Further, the promising molecules were subjected for checking their activity on other molecular targets in SARS-CoV-2 like spike protein S1, RNA dependent RNA polymerase (RdRp), and angiotensin converting enzyme 2 (ACE2) receptor. But the compounds were found non-effective on the rest of the molecular targets. Conclusion: Sorivudine alone or a combination of sorivudine and noricumazole B may be administered to impede viral replication, though the predicted drug likeliness of noricumazole B is not much satisfactory. These observations are solely based on the results from blind docking with protein molecules and need to be further corroborated with experimental results.Export Options
About this article
Cite this article as:
Rana Shiwani , Panwar Meghali and Ghosh Sundar Kalyan *, Docking Studies with Multiple Molecular Targets Associated with SARSCoV- 2 for Drug Repurposing, Coronaviruses 2021; 2 (8) : e260721189170 . https://dx.doi.org/10.2174/2666796701999201216111613
DOI https://dx.doi.org/10.2174/2666796701999201216111613 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vitro Data of Current Therapies for SARS-CoV-2
Current Medicinal Chemistry COVID-19: Pathogenesis and Pharmacological Basis for Use of Passive Antibody Therapy
Current Drug Therapy Withdrawal Notice: Update on the SARS-CoV-2 (COVID-19) Outbreak: A Global Pandemic Challenge
Coronaviruses Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces
Endocrine, Metabolic & Immune Disorders - Drug Targets Doctoral Degree Surplus and Dwindling Quality: A Perilous Blend for Young Scientists in Tackling COVID-19 Like Pandemics
Combinatorial Chemistry & High Throughput Screening Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Respiratory Therapeutic Strategies in Children and Adolescents with COVID-19: A Critical Review
Current Pediatric Reviews Therapeutic Approaches for COVID-19 Based on the Interferon-Mediated Immune Responses
Current Signal Transduction Therapy <i>In Silico</i> Identification of New Anti-SARS-CoV-2 Agents from Bioactive Phytocompounds Targeting the Viral Spike Glycoprotein and Human TLR4
Letters in Drug Design & Discovery Drug Re-purposing Approach and Potential Therapeutic Strategies to Treat COVID-19
Mini-Reviews in Medicinal Chemistry Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Current Drug Targets Clinical Characteristics and CT Imaging Features of COVID-19 on Admission: A Retrospective Study
Current Medical Imaging The Role of Advanced Technologies Supplemented with Traditional Methods in Pharmacovigilance Sciences
Recent Patents on Biotechnology Recent Patents on Treatment of Severe Acute Respiratory Syndrome (SARS)
Recent Patents on Anti-Infective Drug Discovery SVM Prediction of Ligand-binding Sites in Bacterial Lipoproteins Employing Shape and Physio-chemical Descriptors
Protein & Peptide Letters Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Characterizing the Zika Virus Genome – A Bioinformatics Study
Current Computer-Aided Drug Design Nutritional Intervention for the Treatment and Prevention Against Novel Coronavirus-19
Coronaviruses COVID-19: An Opinion of Prevention and Dietary Based Management Hypothesis
Coronaviruses Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses
Current Topics in Medicinal Chemistry